Evidence from clinical trials suggests that refractory hypertension is increasingly common. The underlying mechanisms are largely unknown but recent data have implicated increased aldosterone activity as an important mediator of resistance to routinely used antihypertensive agents.
|Number of pages||6|
|Journal||Current Opinion in Endocrinology, Diabetes and Obesity|
|Publication status||Published - 2007|